Abstract
Matching-adjusted indirect comparison of guselkumab versus risankizumab in patients with moderate-to-severe plaque psoriasis: Change in baseline Psoriasis Area and Severity Index from week 4 to 40
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have